Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s

Multiple myeloma (MM) is the second most prevalent hematologic malignancy. Although the use of bortezomib (BTZ) significantly improves MM therapy, intrinsic and acquired drug resistance to BTZ remains a major clinical problem. In this study, we find that Cdc37, a key co-chaperone of Hsp90, is downre...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncogenesis
Asıl Yazarlar: Zang, Meirong, Guo, Jiaojiao, Liu, Lanting, Jin, Fengyan, Feng, Xiangling, An, Gang, Qin, Xiaoqi, Wu, Yangbowen, Lei, Qian, Meng, Bin, Zhu, Yinghong, Guan, Yongjun, Deng, Shuhui, Hao, Mu, Xu, Yan, Zou, Dehui, Wu, Minghua, Qiu, Lugui, Zhou, Wen
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7058164/
https://ncbi.nlm.nih.gov/pubmed/32139666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-020-0216-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller